67 Asahi-machi, Kurume
830-0011, JAPAN
Daisan Hakata Kaisei Bldg.,
1-3-6, Hakata-eki-minami,
Hakata-ku, Fukuoka-shi,
Fukuoka, 812-0016, Japan
TEL: +81-92-437-4188
FAX: +81-92-437-4182
E-mail:jshilc2021@c-linkage.co.jp
We are delighted to have you join us for Japan Society of Hepatology International Liver Conference 2021 on the theme of “Pioneering New Frontier in Liver Cancer-From Bench to Bedside and Beyond-“. The scientific program committee members are responsible for organizing a conference that aims to highlight cutting-edge research, emerging clinical trends and hot topics of interest in liver cancer.
Liver cancer is the third leading cause of cancer-related death and ranks the sixth most common neoplasm, with 841,080 diagnosed and 781,631 deaths globally in 2018. These numbers are gradually increasing. Recently, several kinds of molecular targeted agents have become available for patients with advanced liver cancer. In addition, atezolizumab (anti-PD-L1 antibody) plus bevacizumab (anti-VEGF antibody) has proven to be superior to sorafenib in phase 3 randomized controlled trial. These new drugs will cause a drastic paradigm change for the treatment of liver cancer. We are looking forward to discussing new findings in basic and clinical researches and share the knowledge in liver cancer.
The scientific program will consist of invited lectures, plenary sessions, symposia, and free papers which contribute to deepening your understanding of liver cancer. The conference encourages the submission of abstract on research for oral and poster presentations through the conference website. We hope the pandemic of COVID-19 will subside and many hepatologists will get together in the bran-new conference center in Fukuoka. We would appreciate your submission and anticipate a large number of entries, which will facilitate active discussions.
We hope to meet you in Fukuoka.
Respectfully yours,